Clinical Trials Directory

Trials / Completed

CompletedNCT00524498

A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Otsuka Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of a continuous hepatic arterial infusion combination therapy with OPC-18 and 5-FU versus BST in patients with highly advanced hepatocellular carcinoma for which resection therapy or local therapy is inapplicable due to advanced vascular invasion.

Conditions

Interventions

TypeNameDescription
DRUGOPC-18OPC-18: 500IU \* 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery
DRUGcisplatininfusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day

Timeline

Start date
2007-09-01
Primary completion
2010-01-01
Completion
2010-01-01
First posted
2007-09-03
Last updated
2015-10-15

Locations

7 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT00524498. Inclusion in this directory is not an endorsement.